keyword
MENU ▼
Read by QxMD icon Read
search

Eye anti-VEGF

keyword
https://www.readbyqxmd.com/read/27913654/novel-small-molecule-jp-153-targets-the-src-fak-paxillin-signaling-complex-to-inhibit-vegf-induced-retinal-angiogenesis
#1
Jordan J Toutounchian, Jayaprakash Pagadala, Duane D Miller, Jerome Baudry, Frank Park, Edward Chaum, Charles R Yates
Targeting vascular endothelial growth factor (VEGF) is a common treatment strategy for neovascular eye disease, a major cause of vision loss in diabetic retinopathy and age-related macular degeneration. However, the decline in clinical efficacy over time in many patients suggests that monotherapy of anti-VEGF protein therapeutics may benefit from adjunctive treatments. Our previous work has shown that through decreased activation of the cytoskeletal protein paxillin, growth factor-induced ischemic retinopathy in the murine oxygen-induced retinopathy model could be inhibited...
January 2017: Molecular Pharmacology
https://www.readbyqxmd.com/read/27913442/comparison-of-anti-vegf-therapies-on-fibrovascular-pigment-epithelial-detachments-in-age-related-macular-degeneration
#2
Adrian Au, Vishal S Parikh, Rishi P Singh, Justis P Ehlers, Alex Yuan, Aleksandra V Rachitskaya, Jonathan E Sears, Sunil K Srivastava, Peter K Kaiser, Andrew P Schachat, Daniel F Martin, Yasha Modi
BACKGROUND: The aim is to compare the therapeutic effects of three antivascular endothelial growth factor (VEGF) drugs (bevacizumab, aflibercept and ranibizumab) on fibrovascular pigment epithelial detachments (fvPEDs) in age-related macular degeneration (AMD). METHODS: This was a retrospective, comparative, consecutive case series of 88 unique eyes with fvPEDs in neovascular AMD treated with anti-VEGF monotherapy for a minimum of 6 months. All eyes were treatment naive...
December 2, 2016: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/27911420/-role-of-immunological-factors-in-the-development-of-myopic-choroidal-neovascularization
#3
A G Shchuko, N V Zaitseva, T N Yur'eva, E R Chernykh, I M Mikhalevich, A V Grigor'eva
AIM: To study the concentration of cytokines in the aqueous humor of the anterior chamber in patients with myopic choroidal neovascularization (mCNV) and to compare the results to their ophthalmic status. MATERIAL AND METHODS: A total of 19 patients (19 eyes) with mCNV treated with intravitreal ranibizumab were included in the study. The control group consisted of 15 patients (15 eyes) with myopia who had cataract surgery. Age, sex, and refractive error distribution were similar to that in the study group...
2016: Vestnik Oftalmologii
https://www.readbyqxmd.com/read/27895936/neovascular-glaucoma-a-review
#4
REVIEW
Gustavo B Rodrigues, Ricardo Y Abe, Camila Zangalli, Savio L Sodre, Flavia A Donini, Danilo C Costa, Andre Leite, Joao P Felix, Marcelo Torigoe, Alberto Diniz-Filho, Homero Gusmão de Almeida
Neovascular glaucoma (NVG) is a secondary glaucoma generally associated with poor visual prognosis. The development of new vessels over the iris and the iridocorneal angle can obstruct aqueous humor outflow and lead to increased intraocular pressure. The underlying pathogenesis in most cases is posterior segment ischemia, which is most commonly secondary to proliferative diabetic retinopathy or central vein retinal occlusion. The neovascularization process in the eye is driven by the events that alter the homeostatic balance between pro-angiogenic factors, such as the vascular endothelial growth factor and anti-angiogenic factors, such as the pigment-epithelium-derived factor...
2016: International Journal of Retina and Vitreous
https://www.readbyqxmd.com/read/27884546/-results-of-trabeculectomy-with-anti-vgef-therapy-in-the-treatment-of-neovascular-glaucoma-secondary-to-retinal-vein-occlusion-report-of-21%C3%A2-cases-followed-at-bukavu-eye-clinic-from-january-1%C3%A2-to-december-31th-2015
#5
T B Kabesha, D Kabesha, V Maloba, C Mwamba, B Chenge, A Mukalay
PURPOSE: To evaluate the results of anti-VGEF with trabeculectomy in the treatment of neovascular glaucoma, a severe complication of retinal vein occlusion (RVO). PATIENTS AND METHODS: This is a prospective case series of consecutive patients with neovascular glaucoma secondary to retinal vein occlusion. All patients underwent panretinal photocoagulation and a mean of 3 anti-VEGF injections prior to trabeculectomy. Ophthalmic parameters were recorded pre- and postoperatively: visual acuity (VA), intraocular pressure (IOP), iris examination, gonioscopy and fundus examination, and as necessary, fluorescein angiography...
November 21, 2016: Journal Français D'ophtalmologie
https://www.readbyqxmd.com/read/27868009/the-potential-of-anti-vegf-vasotide-by-eye-drops-to-treat-proliferative-retinopathies
#6
COMMENT
Jennifer L Wilkinson-Berka, Devy Deliyanti
No abstract text is available yet for this article.
October 2016: Annals of Translational Medicine
https://www.readbyqxmd.com/read/27865689/retinal-oximetry-during-treatment-of-retinal-vein-occlusion-by-ranibizumab-in-patients-with-high-blood-pressure-and-dyslipidemia
#7
C Keilani, A Halalchi, D Wakpi Djeugue, A Regis, S Abada
INTRODUCTION: In the present study, we examined retinal vascular oxygen saturation in patients with retinal vein occlusion (RVO), high blood pressure (HBP) and dyslipidemia, before and during intravitreal vascular endothelial growth factor (VEGF) injection (ranibizumab). METHODS: We retrospectively reviewed the medical records of six patients with visual acuity (VA) reduced by macular edema (ME) secondary to RVO with HBP and dyslipidemia, who underwent intravitreal anti-VEGF injection between October 2014 and February 2015 in the department of ophthalmology of François-Quesnay Hospital at Mantes-la-Jolie (France)...
November 16, 2016: Journal Français D'ophtalmologie
https://www.readbyqxmd.com/read/27863843/score2-report-2-study-design-and-baseline-characteristics
#8
Ingrid U Scott, Paul C VanVeldhuisen, Michael S Ip, Barbara A Blodi, Neal L Oden, Maria Figueroa, Pravin U Dugel
PURPOSE: To describe the design and baseline characteristics of participants in the Study of COmparative Treatments for REtinal Vein Occlusion 2 (SCORE2) and to compare with cohorts from other retinal vein occlusion trials. DESIGN: Phase III prospective, multicenter, randomized clinical trial designed to assess whether intravitreal bevacizumab is noninferior to intravitreal aflibercept for treatment of decreased vision attributable to macular edema associated with central retinal vein occlusion (CRVO) or hemiretinal vein occlusion (HRVO)...
November 15, 2016: Ophthalmology
https://www.readbyqxmd.com/read/27853011/long-term-effect-of-anti-vascular-endothelial-growth-factor-injections-on-intraocular-pressure
#9
Ashiyana Nariani, Blake Williams, Seenu M Hariprasad
OBJECTIVE: There is a substantial debate in the ophthalmology community about whether anti-vascular endothelial growth factor (VEGF) injections result in a long-term increase in intraocular pressure (IOP). DESIGN: We performed a retrospective study to investigate how the number and timing of intravitreal injections in patients with age-related macular degeneration (AMD) and diabetic macular edema (DME) affect IOP over time. METHODS: We collected long-term IOP data on patients receiving anti-VEGF injections at our institution...
September 2016: Indian Journal of Ophthalmology
https://www.readbyqxmd.com/read/27847634/initiation-of-intravitreal-aflibercept-injection-treatment-in-patients-with-diabetic-macular-edema-a-review-of-vivid-dme-and-vista-dme-data
#10
Focke Ziemssen, Patricio G Schlottman, Jennifer I Lim, Hansjürgen Agostini, Gabriele E Lang, Francesco Bandello
BACKGROUND: Diabetic macular edema (DME) shows a gradual and sustained functional and morphologic response to anti-vascular endothelial growth factor (VEGF) drugs, but the optimal schedule for initiation of anti-VEGF therapy is not known. This study evaluates the treatment response behavior of DME in the Phase 3 trials of intravitreal aflibercept, with 5 initial intravitreal aflibercept injections (IAI), 2 mg every 4 weeks (2q4), in the upload phase. METHODS: This post hoc pooled analysis of the VISTA-DME (NCT01363440) and VIVID-DME (NCT01331681) trials evaluated the change in best-corrected visual acuity (BCVA) and central retinal thickness (CRT) during the upload phase, using pooled data from both IAI treatment groups [2q4 and 2 mg every 8 weeks (2q8)]...
2016: International Journal of Retina and Vitreous
https://www.readbyqxmd.com/read/27847624/prevalence-of-outer-retinal-tubulation-in-eyes-with-choroidal-neovascularization
#11
Richard Geraldo Giachetti Filho, Leandro Cabral Zacharias, Thaís Vera Monteiro, Rony Carlos Preti, Sérgio Gianoti Pimentel
BACKGROUND: Outer retinal tubulations (ORTs) are branching tubular structures located in the outer nuclear layer of the retina. The goal of this study is to determine the prevalence of ORTs observed in eyes with choroidal neovascularization (CNV) undergoing treatment with anti-angiogenic intravitreous injection (IVI) with anti-VEGF (vascular endothelial growth factor) at the Ophthalmology Department of a tertiary hospital in São Paulo, Brazil. METHODS: This is a descriptive study based on medical charts and Spectral-domain Optical Coherence Tomography (Sd-OCT) scans of 142 patients (158 eyes) treated between 2012 and 2014 with IVI of anti-VEGF for CNV...
2016: International Journal of Retina and Vitreous
https://www.readbyqxmd.com/read/27847620/conversion-back-to-bevacizumab-or-ranibizumab-for-recurrent-neovascular-activity-with-aflibercept-in-age-related-macular-degeneration-a-case-series
#12
Geraldine R Slean, Kornwipa Hemarat, Rahul N Khurana, Jay M Stewart
BACKGROUND: Neovascular age-related macular degeneration often requires chronic therapy with anti-VEGF agents, and patients with recurrent disease are challenging to manage. METHODS: This retrospective case series evaluates patients who were switched from bevacizumab or ranibizumab to aflibercept and then back again because of recurrent fluid on optical coherence tomography (OCT) by reporting changes in OCT measurements over the course of medication changes. RESULTS: Twenty-one eyes in nineteen patients received an average of 20...
2016: International Journal of Retina and Vitreous
https://www.readbyqxmd.com/read/27843227/combined-argon-laser-photocoagulation-and-antivascular-endothelial-growth-factor-for-management-of-macular-polypoidal-choroidal-vasculopathy
#13
Parveen Sen, S Vinay Kumar, Muna Bhende, Tarun Sharma
AIM: To evaluate the efficacy of combination therapy of argon laser photocoagulation and intravitreal antivascular endothelial growth factor (VEGF) injection in idiopathic polypoidal choroidal vasculopathy (PCV) involving macula. MATERIALS AND METHODS: A retrospective interventional study involving 12 eyes of 11 patients diagnosed with PCV involving the macula on indocyanine green angiography (ICGA). Intravitreal anti-VEGF was given in eyes with significant subretinal/sub retinal pigment epithelium hemorrhage or exudation...
September 2016: Oman Journal of Ophthalmology
https://www.readbyqxmd.com/read/27826933/a-comparison-of-responses-to-intravitreal-bevacizumab-ranibizumab-or-aflibercept-injections-for-neovascular-age-related-macular-degeneration
#14
Dae Hyun Park, Hae Jung Sun, Sung Jin Lee
PURPOSE: To compare the responses of intravitreal injections of bevacizumab, ranibizumab, or aflibercept for the treatment of neovascular age-related macular degeneration (nAMD). METHODS: This retrospective study examined 232 eyes of 232 patients who received intravitreal anti-vascular endothelial growth factor (VEGF) injections due to treatment-naïve nAMD. All patients, who were followed-up for at least 1 year, were treated with intravitreal injections monthly until 3 months, and then as needed...
November 8, 2016: International Ophthalmology
https://www.readbyqxmd.com/read/27818255/protein-delivery-to-the-back-of-the-eye-barriers-carriers-and-stability-of-anti-vegf-proteins
#15
REVIEW
Krishna Radhakrishnan, Nirmal Sonali, Miguel Moreno, Jayabalan Nirmal, Alexandra A Fernandez, Subbu Venkatraman, Rupesh Agrawal
Utilization of the full clinical potential of many novel therapeutic proteins designed for diseases affecting the posterior segment of the eye has often been limited because of their inherent instability and the difficulty in overcoming various ocular barriers. Intravitreal injection is currently the only approved mode of administration, although it is suboptimal because it is painful and has to be done every 1-2 months as a result of high protein clearance rates from the vitreous humor. In this review, we discuss the status of protein drug delivery to back of the eye in terms of novel protein drugs developed, physiological barriers encountered, strategies for carrier design to overcome these limitations, and protein stability...
November 3, 2016: Drug Discovery Today
https://www.readbyqxmd.com/read/27815675/-what-can-anti-vegf-therapy-achieve-in-clinical-routine-effectiveness-of-anti-vegf-therapy-in-patients-with-macular-diseases-in-clinical-routine-on-1492-eyes-in-austria
#16
K Wiesinger, P Reinelt, A Ennemoser, M Edelmayr, U Schönherr
BACKGROUND: The aim of this user observational study was to illustrate the effectiveness of intravitreal operative medication administration (IVOM) in the clinical routine. DESIGN: A monocentric, single arm, prospective study. MATERIAL AND METHODS: Included in this study were all patients in whom a macular edema was diagnosed during an ophthalmological examination at the Barmherzigen Brüdern Hospital in Linz from November 2012 to August 2014 and who were treated as outpatients or day clinic patients with IVOM using anti-vascular endothelial growth factor (VEGF)...
November 4, 2016: Der Ophthalmologe: Zeitschrift der Deutschen Ophthalmologischen Gesellschaft
https://www.readbyqxmd.com/read/27810558/single-ocular-injection-of-a-sustained-release-anti-vegf-delivers-6months-pharmacokinetics-and-efficacy-in-a-primate-laser-cnv-model
#17
Peter Adamson, Thomas Wilde, Eric Dobrzynski, Caroline Sychterz, Rodd Polsky, Edit Kurali, Richard Haworth, Chi-Man Tang, Justyna Korczynska, Fiona Cook, Irene Papanicolaou, Lemy Tsikna, Chris Roberts, Zoe Hughes-Thomas, James Walford, Daniel Gibson, John Warrack, Jos Smal, Ruud Verrijk, Paul E Miller, T Michael Nork, Jeffery Prusakiewicz, Timothy Streit, Steven Sorden, Craig Struble, Brian Christian, Ian R Catchpole
A potent anti-vascular endothelial growth factor (VEGF) biologic and a compatible delivery system were co-evaluated for protection against wet age-related macular degeneration (AMD) over a 6month period following a single intravitreal (IVT) injection. The anti-VEGF molecule is dimeric, containing two different anti-VEGF domain antibodies (dAb) attached to a human IgG1 Fc region: a dual dAb. The delivery system is based on microparticles of PolyActive™ hydrogel co-polymer. The molecule was evaluated both in vitro for potency against VEGF and in ocular VEGF-driven efficacy models in vivo...
November 1, 2016: Journal of Controlled Release: Official Journal of the Controlled Release Society
https://www.readbyqxmd.com/read/27793821/natural-history-and-effect-of-therapeutic-interventions-on-subretinal-fluid-causing-foveal-detachment-in-macular-telangiectasia-type-2
#18
Hemal Mehta, Simone Müller, Catherine A Egan, Simona Degli Esposti, Adnan Tufail, Dawn A Sim, Frank G Holz, Andrew C Browning, Winfried M Amoaku, Peter Charbel Issa, Mark C Gillies
AIM: To report the natural history of subretinal fluid (SRF) causing foveal detachment in macular telangiectasia type 2 (MacTel) and our experience of therapeutic intervention with intravitreal steroids or antivascular endothelial growth factor inhibitor (anti-VEGF) agents in some cases. METHODS: Retrospective case series. Three of the MacTel study's largest registries were searched to identify eyes with foveal detachment. RESULTS: We identified 7 eyes from 6 exclusively female patients...
October 28, 2016: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/27790618/designer-leptin-receptor-antagonist-allo-aca-inhibits-vegf-effects-in-ophthalmic-neoangiogenesis-models
#19
Roberta Coroniti, Rafal Fario, Didier J Nuno, Laszlo Otvos, Laura Scolaro, Eva Surmacz
Experimental and clinical data suggest that pro-angiogenic, pro-inflammatory and mitogenic cytokine leptin can be implicated in ocular neovascularization and other eye pathologies. At least in part, leptin action appears to be mediated through functional interplay with vascular endothelial growth factor (VEGF). VEGF is a potent regulator of neoangiogenesis and vascular leakage with a proven role in conditions such as proliferative diabetic retinopathy, age-related macular degeneration and diabetic macular edema...
2016: Frontiers in Molecular Biosciences
https://www.readbyqxmd.com/read/27784073/retinal-hemodynamics-seen-on-optical-coherence-tomography-angiography-before-and-after-treatment-of-retinal-vein-occlusion
#20
Norihiro Suzuki, Yoshio Hirano, Taneto Tomiyasu, Yuya Esaki, Akiyoshi Uemura, Tsutomu Yasukawa, Munenori Yoshida, Yuichiro Ogura
Purpose: This study evaluates the retinal hemodynamics using optical coherence tomography angiography (OCTA) before and after anti-vascular endothelial growth factor (VEGF) therapy in patients with macular edema associated with retinal vein occlusion (RVO). Methods: Twelve patients (23 eyes; mean age, 64 years) were included (eight eyes with branch RVO, four with central RVO, and 11 unaffected fellow eyes. The best-corrected visual acuity (BCVA) and central retinal thickness (CRT) were measured before and 6 months after treatment...
October 1, 2016: Investigative Ophthalmology & Visual Science
keyword
keyword
36614
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"